Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine
- Development stage
- Unknown
- Lead developer
- Biken
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Tetrabik is a quadrivalent combination vaccine developed by Biken (The Research Foundation for Microbial Diseases of Osaka University) for the prevention of diphtheria, tetanus, pertussis, and poliomyelitis. It contains diphtheria toxoid, tetanus toxoid, acellular pertussis components (typically pertussis toxoid and filamentous hemagglutinin), and inactivated poliovirus (IPV) derived from Sabin strains (sIPV). Tetrabik is primarily utilized in the Japanese pediatric immunization schedule, often administered as a primary series in infants. It serves as a standard-of-care comparator in clinical trials for newer pentavalent vaccines, such as Gobik (BK1310), which incorporate a Haemophilus influenzae type b (Hib) component. The use of Sabin strains for the inactivated polio component distinguishes it from many global IPV formulations that utilize Salk strains.
- Brand names
- Tetrabik
- Other names
- DPT-IPVDTaP-IPVadsorbed diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain) vaccine
02
Targets
PV (Poliovirus (Types 1, 2, and 3))Diphtheria toxin
Beyond the preview
Go deeper on diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine.